Literature DB >> 28385177

Effect of Fontan-Associated Morbidities on Survival With Intact Fontan Circulation.

Kiona Y Allen1, Tacy E Downing2, Andrew C Glatz2, Lindsay S Rogers3, Chitra Ravishankar2, Jack Rychik2, Stephanie Fuller4, Lisa M Montenegro5, James M Steven5, Thomas L Spray4, Susan C Nicolson5, James William Gaynor4, David J Goldberg6.   

Abstract

Although survival after the Fontan operation has improved, little is known about the burden of major medical morbidities associated with the modern total cavopulmonary connection (TCPC). A total of 773 consecutive patients who underwent a first Fontan operation at our institution between 1992 and 2009 were retrospectively reviewed. All subjects underwent TCPC (53% lateral tunnel, 47% extracardiac conduit). Median length of follow-up was 5.3 years (interquartile range 1.4 to 11.2), and 30% had follow-up >10 years. Freedom from a composite medical morbidity outcome (protein-losing enteropathy, plastic bronchitis, serious thromboembolic event, or tachyarrhythmia) was 47% at 20 years (95% confidence interval [CI] 38 to 55). Independent risk factors for morbidity included pre-Fontan atrioventricular valve regurgitation (hazard ratio [HR] 1.7, 95% CI 1.2 to 2.4, p = 0.001), pleural drainage >14 days (HR 1.5, 95% CI 1.01 to 2.2, p = 0.04), and longer cross-clamp time (HR 1.2 per 10 minutes, 95% CI 1.06 to 1.3, p = 0.004) at the time of TCPC. Surgical era, Fontan type, and ventricular morphology were not associated with the composite outcome. Presence of Fontan-associated morbidity was associated with a 36-fold increase in the risk of subsequent Fontan takedown, heart transplantation, or death (95% CI 17 to 76, p <0.001). For patients without any component of the composite outcome, freedom from Fontan failure was 98% at 20 years (95% CI 96 to 99). Medical morbidities after TCPC are common and significantly reduce the longevity of the Fontan circulation. However, for those patients who remain free from the composite morbidity outcome, 20-year survival with intact Fontan circulation is encouraging.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28385177     DOI: 10.1016/j.amjcard.2017.03.004

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

1.  Routine Surveillance Catheterization is Useful in Guiding Management of Stable Fontan Patients.

Authors:  Neil D Patel; Patrick M Sullivan; Arash Sabati; Allison Hill; Chelsea Maedler-Kron; Shengmei Zhou; Nick Shillingford; Roberta Williams; Cheryl Takao; Sarah Badran
Journal:  Pediatr Cardiol       Date:  2020-01-24       Impact factor: 1.655

2.  Exercise Performance at Increased Altitude After Fontan Operation: Comparison to Normal Controls and Correlation with Cavopulmonary Hemodynamics.

Authors:  Michael V Di Maria; Sonali S Patel; Julie C Fernie; Christopher M Rausch
Journal:  Pediatr Cardiol       Date:  2020-01-31       Impact factor: 1.655

3.  Risk Factors for Prolonged Pleural Effusion After Extracardiac Fontan Operation.

Authors:  Geena Kim; Hoon Ko; Joung-Hee Byun; Hyoung Doo Lee; Hyungtae Kim; Si Chan Sung; Kwang Ho Choi
Journal:  Pediatr Cardiol       Date:  2019-08-21       Impact factor: 1.655

4.  Trends in Discharge Prescription of Digoxin After Norwood Operation: An Analysis of Data from the Pediatric Health Information System (PHIS) Database.

Authors:  Michael L O'Byrne; Lihai Song; Jing Huang; David J Goldberg; Monique M Gardner; Chitra Ravishankar; Jonathan J Rome; Andrew C Glatz
Journal:  Pediatr Cardiol       Date:  2021-02-02       Impact factor: 1.655

5.  Functional lymphatic reserve capacity is depressed in patients with a Fontan circulation.

Authors:  Sheyanth Mohanakumar; Benjamin Kelly; Aida Luiza Ribeiro Turquetto; Mathias Alstrup; Luciana Patrick Amato; Milena Schiezari Ru Barnabe; João Bruno Dias Silveira; Fernando Amaral; Paulo Henrique Manso; Marcelo Biscegli Jatene; Vibeke Elisabeth Hjortdal
Journal:  Physiol Rep       Date:  2021-06

6.  Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases.

Authors:  Michael L O'Byrne; Jennifer A Faerber; Hannah Katcoff; Jing Huang; Jonathan B Edelson; David M Finkelstein; Bethan A Lemley; Christopher M Janson; Catherine M Avitabile; Andrew C Glatz; David J Goldberg
Journal:  Am Heart J       Date:  2021-09-25       Impact factor: 4.749

Review 7.  Where Is the "Optimal" Fontan Hemodynamics?

Authors:  Hideo Ohuchi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

8.  Fontan Circulation of the Next Generation: Why It's Necessary, What it Might Look Like.

Authors:  Shelby Kutty; Marshall L Jacobs; W Reid Thompson; David A Danford
Journal:  J Am Heart Assoc       Date:  2019-12-19       Impact factor: 5.501

9.  GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation.

Authors:  Sophie L Meyer; Djoeke Wolff; Floris-Jan S Ridderbos; Graziella Eshuis; Hans Hillege; Tineke P Willems; Tjark Ebels; Joost P van Melle; Rolf M F Berger
Journal:  J Am Heart Assoc       Date:  2020-05-08       Impact factor: 5.501

10.  Risk Factors for Prolonged Pleural Effusion Following Total Cavopulmonary Connection Surgery: 9 Years' Experience at Fuwai Hospital.

Authors:  Qipeng Luo; Wei Zhao; Zhanhao Su; Yiwei Liu; Yuan Jia; Liang Zhang; Hongbai Wang; Yinan Li; Xie Wu; Shoujun Li; Fuxia Yan
Journal:  Front Pediatr       Date:  2019-11-07       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.